Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04605094 |
|
Recruitment Status :
Terminated
(The study did not meet the primary endpoint.)
First Posted : October 27, 2020
Last Update Posted : January 5, 2023
|
Sponsor:
AstraZeneca
Collaborator:
Iqvia Pty Ltd
Information provided by (Responsible Party):
AstraZeneca
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | April 25, 2022 |
| Actual Study Completion Date : | September 13, 2022 |